GammaCan Announces Commencement of Phase II Clinical Trial

GammaCan International, a developer of immunotherapies for cancer and other serious conditions, has received approval from the institutional review board of a leading medical center for the initiation of a clinical trial in Israel.

The Phase II clinical trial of GCAN 101 will include up to 30 patients suffering from metastatic melanoma, or metastatic prostate or colon cancers.

The patented GCAN 101 therapy is based on Intravenous Immunoglobulin (IVIg), a concentrated form of disease-fighting antibodies naturally occurring in human blood. Based on the company's preclinical results and year-long clinical experience with IVIg, the company believes that this new therapy may open an exciting new treatment option that is safe and effective, without the toxic side effects of traditional chemotherapy.